Acromegaly Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Ionis, Crinetics, Camurus, Aquestive, Peptron, DexTech

Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 15+ key pharma and biotech companies are working on 15+ pipeline drugs in the Acromegaly therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Acromegaly Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Acromegaly Market

The Acromegaly Pipeline report embraces in-depth commercial, regulatory, and Acromegaly clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Acromegaly drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Acromegaly Pipeline Analysis

The report provides insights into: 

The report provides detailed insights into the emerging therapies for Acromegaly treatment and the aggregate therapies developed by major pharma companies.

It accesses the different Acromegaly therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

It outlines the major Acromegaly companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

The report evaluates the Acromegaly drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Acromegaly therapeutic market.

Analysis of Emerging Acromegaly Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) 

Pre-clinical and Discovery stage candidates

Discontinued and inactive candidates

Route of Administration

Acromegaly pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as






Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody



Small molecule

Gene therapy

Learn How the Acromegaly Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @

Acromegaly Therapeutics Landscape

The current treatment method for acromegaly is focused on preventing the tumor compression of surrounding tissues by excising the disease-causing areas and reducing GH and IGF-1 levels to normal. Although, the primary treatment method for acromegaly is transsphenoidal surgery all the patients are not eligible for surgery. Patients diagnosed with microadenomas and those with macroadenomas not close to other key structures in the brain, such as the nerves supplying the eyes or nearby blood vessels, are recommended for surgery. The cure rate of surgery is about 80% for microadenomas and 40–50% for macroadenomas. For those patients who are not eligible for surgery and those for whom surgery failed to correct GH/IGF-1 hypersecretion, medical treatment with somatostatin analogs (SSAs), dopamine agonists (DA), growth hormone antagonists, and/or radiotherapy can be used.

The physiologic rationale for the use of SSAs in the management of acromegaly is based principally on the inhibitory effect of native somatostatin on GH secretion. The SSAs such as octreotide (Sandostatin) and lanreotide (Somatuline Depot) are used in the treatment of acromegaly.

Different therapeutic methods are available to correct this hormonal disease but the low response rate of treatment methods, the need for multiple treatment approaches, increasing recurrence cases, and the high patient burden have emerged the need for better treatment methods with prolonged effects and high response rate. To meet the unmet needs of the market and to provide better versions of current treatment practices different companies are working robustly. Several therapies are expected to enter the market in the near future.

There are approx. 15+ key companies developing therapies for Acromegaly. Currently, Crinetics Pharmaceuticals is leading the therapeutics market with its Acromegaly drug candidates in the most advanced stage of clinical development.

Acromegaly Companies Actively Working in the Therapeutic Market Include:

Ionis Pharmaceuticals, Crinetics Pharmaceuticals, Camurus, Ono Pharmaceutical, Aquestive Therapeutics, Strongbridge Biopharma, Italfarmaco, Ipsen, Antisense Therapeutics, Dauntless Pharmaceuticals, TTY Biopharm, Peptron, DexTech Medical AB, Rani Therapeutics, OPKO Health, Inc, Amolyt Pharma, Foresee Pharmaceuticals, ADVANZ PHARMA, and many others.

Emerging and Marketed Acromegaly Drugs Covered in the Report Include:

IONIS-GHR-LRX: Ionis Pharmaceuticals

Paltusotine: Crinetics Pharmaceuticals

CAM2029: Camurus

And many more

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Acromegaly Companies Working in the Market @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Acromegaly Treatment Patterns

4. Acromegaly – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Acromegaly Late Stage Products (Phase-III)

7. Acromegaly Mid-Stage Products (Phase-II)

8. Acromegaly Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Acromegaly Discontinued Products

13. Acromegaly Product Profiles

14. Major Acromegaly Companies in the Market

15. Key Products in the Acromegaly Therapeutics Segment

16. Dormant and Discontinued Products

17. Acromegaly Unmet Needs

18. Acromegaly Future Perspectives

19. Acromegaly Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Gastroesophageal Reflux Disease (GERD) Market

“Gastroesophageal Reflux Disease (GERD) Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Gastroesophageal Reflux Disease market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the GERD market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

%d bloggers like this: